TY - JOUR T1 - Management of corticosteroid-induced osteoporosis JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 98 LP - 101 DO - 10.1136/dtb.2010.09.0047 VL - 48 IS - 9 A2 - , Y1 - 2010/09/01 UR - http://dtb.bmj.com/content/48/9/98.abstract N2 - Relevant BNF section: BNF 6.6 Treatment with corticosteroids can adversely affect bone metabolism. In particular, it lowers bone mineral density (BMD) and increases the likelihood of fragility fractures, the hallmarks of osteoporosis, hence the term ‘corticosteroid-induced osteoporosis’.1 Since corticosteroids are used for a wide variety of inflammatory conditions, corticosteroid-induced osteoporosis represents a substantial disease burden. Here we aim to provide advice on prophylaxis and treatment for osteoporosis in adults receiving corticosteroid therapy. ER -